INT230-6 is a combination therapy that is injected directly into tumors. It includes three components: SHAO, which is a proprietary formulation, and two chemotherapy drugs, Vinblastine and Cisplatin. This therapy is being tested to see if it can effectively treat soft tissue sarcomas that cannot be removed by surgery or have spread to other parts of the body. The goal is to see if this treatment can help patients live longer compared to the standard treatments used in the United States.

Liposarcoma – A type of cancer that arises in fat cells, often occurring in the deep soft tissues of the body, such as the thighs or retroperitoneum. It can be classified into subtypes like dedifferentiated, myxoid, round cell, or pleomorphic, each with distinct cellular characteristics. The disease typically presents as a painless, enlarging mass, and its progression can vary depending on the subtype. Over time, the tumor may grow and potentially invade surrounding tissues or metastasize to other parts of the body.

Undifferentiated Pleomorphic Sarcoma – A rare type of soft tissue sarcoma that lacks specific differentiation, making it difficult to classify under a specific cell type. It often presents as a rapidly growing mass, usually in the extremities or retroperitoneum. The disease is characterized by a high degree of cellular atypia and pleomorphism, meaning the cells vary widely in shape and size. As it progresses, it may invade nearby tissues and has the potential to spread to distant sites.

Leiomyosarcoma – A malignant tumor that originates from smooth muscle cells, commonly found in the uterus, gastrointestinal tract, or blood vessels, but can occur in other non-uterine locations. It typically presents as a firm, painless mass and may cause symptoms related to the compression of nearby structures. The disease is known for its aggressive nature and potential to metastasize, particularly to the lungs and liver. As it advances, it can lead to significant local tissue destruction and distant spread.